UF researchers found a gut-derived molecule that boosts lung cancer immunotherapy in mice, shrinking tumors by 50% in resistant cases.

LIR Life Sciences partners with Neuland Labs to develop non-injectable, patch-based obesity treatment using cell-penetrating peptides, backed by a $230,000 Phase 1 budget.

A new Swiss method tracks how antibiotics kill individual bacteria in real time, showing it better predicts treatment success than old tests.

Afghanistan to build $8.7M medical university in Khost with hospital and five faculties.

PromiCell's CAR T therapy for prostate cancer shows early promise in first human trial, to be presented Jan. 12, 2025.

A new AI system, SleepFM, predicts over 130 diseases using one night of sleep data with high accuracy.

Starting Feb. 1, 2026, nitisinone for tyrosinemia type 1 and alkaptonuria will be publicly funded, simplifying access for about 10 patients.

Abivax shares jumped 22% on Jan. 12, 2026, on takeover rumors after Eli Lilly considered a 15 billion euro bid.

The EU approved Sanofi’s Teizeild to delay type 1 diabetes in high-risk patients, based on strong trial results.

Australian scientists developed a targeted immunotherapy for myelofibrosis, a rare blood cancer, based on specific gene mutations.